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OBJECTIVE: To examine a medical records database to deter-
mine the prevalence of insomnia in patients with a history of
drug dependence or abuse. METHODS: Data from April, 1996
to September, 2003 on patients with a diagnosis of drug depen-
dence or abuse (ICD-9 code 303.9, 304–305 [except tobacco use,
305.1]) were extracted from the GE Medical Systems database—
a large outpatient database with input from over 2000 practic-
ing physicians. The insomnia cohort was deﬁned as patients
having either a diagnosis consistent with insomnia (ICD-9 codes
307.4x [x = 1–2, 9] and 780.5x [x = 0, 2]) or a prescription 
for insomnia medication. Demographic characteristics, comor-
bid conditions, and concomitant medications were evaluated.
RESULTS: A total of 13,861 patients in the database constituted
the population with drug dependence or abuse, and 2,479
(17.9%) of these composed the insomnia cohort. This insomnia
prevalence rate was more than twice that in the population
without reported drug abuse or dependence (7.4%; 115,487 of
1,567,751). Alcohol abuse was the most prevalent type of drug
dependence or abuse diagnosed in the insomnia cohort. The most
frequently reported comorbidities were depressive disorders
(32.4%), neurotic disorders (28.6%), and other unspeciﬁed dis-
orders of the back (23.4%). Analgesics (70.3%), psychothera-
peutics (81.1%), and anti-infective agents (61.4%) were among
the most common concomitant medications. CONCLUSIONS:
Patients with drug dependence or abuse were more than twice
as likely to have a diagnosis or prescription for insomnia med-
ication compared with patients without drug dependence or
abuse. The insomnia cohort had a high rate of comorbidities and
prescriptions for concomitant medications. These data suggest
that insomnia is a common comorbid problem in patients with
diagnosed histories of drug dependence or abuse. Since this spe-
ciﬁc population has unique issues and concerns related to use 
of prescription sedative hypnotic medications, further studies
examining safe, nonaddicting, and effective therapies for comor-
bid insomnia should be pursued.
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OBJECTIVES: Although the clinical beneﬁts of insomnia phar-
macotherapy have been studied, no systematic assessment of the
economic value has been published. This study assessed the cost
effectiveness of longer-term therapy with eszopiclone for chronic
primary insomnia in adults. METHODS: A decision analytical
model was developed on the basis of the results of a six-month
placebo-controlled trial, which demonstrated that eszopiclone 3
mg signiﬁcantly improved sleep and daytime function measures
versus placebo in adults with primary insomnia. These data were
supplemented with quality-of-life and cost data from published
literature and claims databases. Patients were classiﬁed as either
recovered or not recovered from insomnia based upon a com-
posite index of eight sleep and daytime function measures col-
lected during the trial. RESULTS: Compared to non-recovered
patients, patients classiﬁed as recovered had lower monthly costs
($866 vs. $1172) and higher quality-adjusted-life-year [QALY]
weight (0.8413 vs. 0.7644). Signiﬁcantly more treated patients
(versus placebo) recovered from insomnia (all p-values < 0.001).
At study termination, eszopiclone patients were 2.5 times more
likely to have recovered than placebo. Six-month eszopiclone
treatment was projected to reduce direct and indirect costs by
$311 and $208 per patient, respectively. Eszopiclone adminis-
tration was associated with a cost of $669 per patient. Overall,
six-month eszopiclone use was associated with a net cost increase
of $150 and a net QOLY gain of 0.0092 per patient. Conse-
quently, the incremental cost associated with eszopiclone 
was approximately $16,300 per QALY gained ($150/0.0092). 
Sensitivity analyses using a variety of scenarios conﬁrmed that
eszopiclone costs less than $50,000 per QALY gained. CON-
CLUSIONS: In this analysis, eszopiclone treatment was cost-
effective with costs per QALY gained within an acceptable range.
This result derives primarily from the beneﬁt observed in the clin-
ical trial that patients treated with eszopiclone were 2.5 times
more likely to recover from insomnia.
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OBJECTIVES: To develop a budget impact model estimating
potential costs of adding new drugs to the formulary using
medical claims and clinical trial data using a case study of eszopi-
clone, an insomnia medication awaiting approval. METHODS:
A 3-step process estimated the costs of treating insomnia using
eszopiclone and other insomnia agents: 1) Insomnia drug efﬁ-
cacy was estimated from published literature on marketed drugs
and from clinical trial reports of eszopiclone. Prior to summa-
rizing trial data, adjustments were made for the different char-
acteristics of each clinical trial (i.e., size, location, patient
characteristics); 2) A multiple regression model was then applied
to the MarketScan claims data (from 85,832 insomnia patients)
and to the clinical trial efﬁcacy data in order to estimate a rela-
tionship between medical expenditures and treatment efﬁcacy.
Patient-reported total sleep time was the primary efﬁcacy
measure, and ﬁve other sleep variables (patient-reported latency
and awakenings, PSG latency, sleep efﬁciency, and wake time
after sleep onset were included in the model; 3) Eszopiclone
expenditures (premium pricing assumed) were estimated by mul-
tiplying eszopiclone efﬁcacy estimates by the regression-based
estimates of expenditures. The regression model additionally
accounts for the impact of other demographics and clinical char-
acteristics that inﬂuence expenditures. A budget impact model
that could be used for any given health plan was then developed.
RESULTS: For a health plan with 100,000 members, the model
estimated that use of eszopiclone decreased annual insomnia
treatment costs by $498,204 using the default efﬁcacy endpoint,
total sleep time. Results were consistent regardless of which efﬁ-
cacy endpoint was used. CONCLUSIONS: Using this modeling
approach, use of eszopiclone is estimated to substantially
decrease annual treatment costs for insomnia patients. The mod-
eling approach used represents an alternative and potentially
effective way of estimating the impact of medications pending
marketing approval.
